TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential. On January 27, TD Cowen analyst Ritu Baral maintained the firm’s Hold rating on Amicus Therapeutics Inc. (NASDAQ:FOLD), as well as the $14.50 price target on the stock. Amicus’s pre-announced fourth-quarter and full-year 2025 total product revenue were modestly above expectations, according to TD Cowen, with Fabry disease medication Galafold delivering a clear outperformance versus consensus estimates, while revenues from Pompe disease medications came in roughly in line with broader Wall Street expectations.
TD Cowen also noted that the strategic landscape for the Amicus Therapeutics Inc. (NASDAQ:FOLD) stock is now largely defined by BioMarin’s agreement to acquire Amicus for $14.50 per share in cash, with the deal already approved by both companies’ boards and expected to close by the second quarter of 2026, subject to shareholder and regulatory approvals. With a fixed takeout price and a clear M&A timeline, the scope for further meaningful appreciation in Amicus Therapeutics Inc. (NASDAQ:FOLD) share price is constrained primarily to potential deal-spread dynamics and low-probability transaction risk, rather than fundamentals-driven multiple expansion, according to the analyst.
Amicus Therapeutics Inc. (NASDAQ:FOLD) is a biotechnology company that focuses on discovering, developing, and delivering medicines for people living with metabolic diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Brazil’s New Crypto Rules Could Change the Market: 5 Altcoins Worth Holding as October Nears
With Q3 financial reports approaching, Samsung Electronics and SK Hynix face "extremely high expectations," testing "global AI trading"
The AI wave is driving a global semiconductor "super cycle," with combined third-quarter operating profits of Samsung and SK Hynix potentially approaching the historical record of 190 trillion won. The competition for HBM4 is intensifying, as agent-based AI pushes storage bandwidth demand up tenfold, making memory truly the "lifeblood" of AI data centers. Two upcoming financial reports will determine whether this boom is merely a flash in the pan or a structural transformation that will reshape the foundation of technology infrastructure.

‘Provide future qualification path’ — Strive challenges MSCI proposal to exclude Bitcoin treasuries
The Fed Just Paused Its Treasury Buying: 5 Altcoins Worth Holding as Liquidity Shifts
